Clinical Evaluation of Topical Coenzyme Q10 in Management of Oral Aphthous Ulcer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03213769

Enrollment

Registered

2017-07-11

Start date

2017-07-31

Completion date

2018-07-31

Last updated

2017-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Aphthous Ulcer

Keywords

oral minor aphthous ulcer, topical Q10 gel, topical antioxidant, oral recurrent aphthous ulcer, oral aphthous stomatitis

Brief summary

Recurrent oral aphthous ulcer is the most common oral lesion in occurrence and one of cause is oxidative stress so investigators need to use antioxidant drugs like topical coenzyme Q10 gel to treat the lesion and more safe for the participants.

Detailed description

Double randomized clinical trial study using two parallel group suffer from oral aphthous ulcer one take antioxidant topical q10gel and other group take placebo carpabol gel two times per day for seven days measuring outcome at fourth and seventh day including pain; healing period and clinical parameters. Sample size of study include 26 in each group.

Interventions

DRUGtopical coenzyme Q10 gel

Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.

DRUGCarpabol gel

placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Masking description

double blind

Intervention model description

controlled randimized clinical trial

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Patients with free medical history and no systemic diseases16. * Patients clinically diagnosed as suffering from symptomatic oral minor aphthous ulcers. * Patients who agreed to take medications.

Exclusion criteria

* Patients suffering from any systemic disease as Crohn's disease, Behcet's disease and others. * Anemic and leukemic patients (using complete blood count investigation) * Patients taking systemic drugs such as systemic steroids and other immunosuppressive therapy. * Patients treated with any oral topical medications 48h before the study27. * Pregnant and lactating mothers.

Design outcomes

Primary

Measure	Time frame	Description
visual analogue scale	7 days	pain

Secondary

Measure	Time frame	Description
scoring system(0-3)	7 days	Erythema surround lesion
cross sectional area William periodontal probe/mm	7 days	Cross sectional area

Contacts

Primary Contactmostafa abdelsamie nafie, master

mostafa.abdelsamie@dentistry.cu.edu.eg+201004165905

Backup ContactAmal Ali, lecturer

amal_ali.2009@yahoo.com+201005204628

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026